Alumis Inc.

1.1 Identity, headquarters, and business model

Alumis Inc. is a late-stage biopharmaceutical company incorporated in Delaware and headquartered at 280 East Grand Avenue, South San Francisco, California 94080. The company's mailing and business address registered with the SEC is confirmed by EDGAR filings under CIK 0001847367. Alumis describes itself as developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company is listed on the Nasdaq Global Select Market under the ticker symbol ALMS, having commenced trading on June 28, 2024. The company was founded in 2021, having emerged from Foresite Labs, the incubation arm of Foresite Capital. Multiple industry sources confirm that Alumis previously operated under the name Esker Therapeutics before rebranding. The company's core business model is clinical-stage drug development with no approved products and no product revenue as of the run date. All operations are financed through equity capital raises, with the company reporting a trailing-twelve-month loss of $1.78 per share as of May 2026. Alumis's commercial thesis rests on developing next-generation, oral small-molecule therapies that can challenge injectable biologics on efficacy while offering the convenience of oral dosing. The company's proprietary precision data analytics platform is used to identify and advance programs across a range of immune-mediated diseases. In addition to its TYK2 inhibitor programs, Alumis has expanded its pipeline to include lonigutamab, a subcutaneously delivered anti-IGF-1R biologic for thyroid eye disease, demonstrating a multi-target approach to immune-mediated disease. The company describes its strategy as building a "pipeline-in-a-pill," seeking to leverage maximal TYK2 inhibition across the IL-23, IL-17, and type I interferon pathways that drive roughly 20 immune-mediated conditions according to the company's genomic analyses.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Founders, leadership, and governance

Martin Babler serves as President, Chief Executive Officer, and Chairman of the Board of Alumis. He joined the company in September 2021 and has been the public face of the organization across all major financing events and clinical milestones. Babler brings deep small-molecule immunology operating experience from prior roles as President and CEO of Principia Biopharma, which was acquired by Sanofi for approximately $3.7 billion in 2021, and from senior positions at Genentech and Eli Lilly. His operator-to-acquisition track record in the same therapeutic area is a significant investor signal and explains Alumis's ability to raise $259 million in Series C financing during a challenging 2024 private biotech market. Jörn Drappa, MD, PhD serves as Chief Medical Officer and has been named in all Phase 3 results announcements; his scientific commentary has been the primary technical voice of the company in external disclosures. John Schroer serves as Chief Financial Officer and led the company's capital markets activity through the IPO and follow-on offering. Roy Hardiman serves as Chief Business and Legal Officer. Mark Bradley serves as Chief Development Officer, with responsibility for clinical operations including the ONWARD and LUMUS programs. The Alumis board of directors as of the run date includes Martin Babler as Chairman; Srinivas Akkaraju, a prominent life sciences investor; Jim Tananbaum, founder and CEO of Foresite Capital, reflecting Foresite's ongoing board-level engagement with the company it incubated; Alan Colowick, Sapna Srivastava, Zhengbin Yao (President and CEO of Zymeworks), and Patrick Machado. The company has not publicly disclosed a COO, named successor plan, or operational deputy to Babler, creating key-person concentration risk for a pre-commercial biotech company at a pivotal regulatory juncture. The original founding team that launched the company under the Esker Therapeutics name in 2021 is not fully disclosed in currently available public sources. The company's public narrative attributes founding to its emergence from Foresite Labs incubation with Martin Babler as a founding operator-CEO; no other founding co-inventor names are confirmed from fetched sources.[CO011, CO012, CO013, CO014, CO015, CO016]

1.3 Funding history and capital stack

Alumis has raised approximately $1.12 billion in aggregate capital from founding through January 2026 across five distinct financing events. The Series A of approximately $70 million was raised in 2021 when the company was operating under the Esker Therapeutics name; multiple industry sources confirm this founding round. The Series B of $200 million was raised in 2022, enabling the company to conduct its Phase 2 STRIDE trial in plaque psoriasis and initiate mid-phase studies in SLE and non-infectious uveitis. The Series C of $259 million, closed in March 2024, was the largest private biotech financing of 2024 at the time of announcement according to Fierce Biotech's fundraising tracker. The round was co-led by Foresite Capital, Samsara BioCapital, and venBio Partners. New investors including Cormorant Asset Management, SR One, and Lilly Asia Ventures joined, while existing backer AyurMaya Capital Management participated. This round funded the pivotal Phase 3 ONWARD program in plaque psoriasis and the Phase 2b LUMUS program in SLE. The IPO on June 28, 2024, raised gross proceeds of approximately $250 million. The IPO was priced at $16.00 per share, the low end of the $16–$18 indicated range, after the company downsized the offering from a planned 17.65 million shares (targeting $274–315 million including over-allotment) to 13,125,000 shares. A concurrent private placement to AyurMaya at the same price added approximately $40 million. ALMS shares traded as low as approximately $12.77 on the first day of trading, falling below the offering price—a signal of muted initial public market reception. In January 2026, following the announcement of positive Phase 3 ONWARD results, Alumis completed an upsized follow-on public offering of 20,297,500 shares at $17.00 per share, raising gross proceeds of approximately $345.1 million (including full exercise of the underwriters' over-allotment option). This offering was led by Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities. The company's unaudited cash position was approximately $308.6 million as of December 31, 2025; following the follow-on, total liquidity exceeded $650 million with management disclosing a runway into approximately late 2027.[CO019, CO020, CO021, CO022, CO023, CO024]

1.4 Pipeline overview and product strategy

Alumis's most advanced product candidate, envudeucitinib, is an oral, highly selective, allosteric inhibitor of TYK2 designed to deliver maximal 24-hour TYK2 inhibition while minimizing off-target binding. The compound was evaluated in the pivotal Phase 3 ONWARD1 and ONWARD2 trials in adults with moderate-to-severe plaque psoriasis; positive topline results were announced on January 6, 2026. In the trials, envudeucitinib met all primary and secondary endpoints with high statistical significance versus placebo. At Week 16, 74% of patients on average achieved PASI 75 and 59% achieved sPGA 0/1. At Week 24, approximately 65% achieved PASI 90 and more than 40% achieved PASI 100 (complete skin clearance). The drug was also superior to the active comparator apremilast across all PASI endpoints at Week 24 (p<0.0001). No new safety signals were identified; common adverse events were headache, nasopharyngitis, upper respiratory tract infections, and acne. The company plans to submit an NDA to the U.S. FDA for envudeucitinib in plaque psoriasis in the second half of 2026. ONWARD3, a long-term extension study assessing durability of response and long-term safety, is ongoing. In SLE, the global Phase 2b LUMUS trial completed enrollment of 408 patients in July 2025; topline data are expected in Q3 2026. The trial is a randomized, double-blind, placebo-controlled study with BICLA response rate at Week 48 as the primary endpoint. Beyond the lead program, Alumis is developing A-005, a CNS-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, currently in Phase 1 clinical development. The third pipeline asset, lonigutamab, is a subcutaneous anti-IGF-1R biologic for thyroid eye disease. The company's precision data analytics platform has also identified additional preclinical programs across undisclosed immune-mediated disease targets. The competitive landscape for envudeucitinib includes BMS Sotyktu (deucravacitinib, approved 2022, PASI 90 ~40% at 24 weeks), Takeda zasocitinib (once-daily TYK2, Phase 3), and J&J's approved oral IL-23 inhibitor icotrokinra—the last of which H.C. Wainwright cited as holding the strongest commercial position in 2026, leading the firm to cut its ALMS price target from $40 to $25.[CO031, CO032, CO033, CO034, CO035, CO036]

1.5 Milestones and chronology

The public record supports a milestone chronology running from Alumis's 2021 founding through its January 2026 capital raise and concurrent Phase 3 results announcement. The financing history is well documented by press releases and SEC filings. The 2021 Series A ($70M) represents the founding capital when the company was Esker Therapeutics; the 2022 Series B ($200M) funded Phase 2 clinical work; the 2024 Series C ($259M) launched the pivotal Phase 3 program; and the June 2024 IPO brought the company to public markets at $16.00 per share, though the stock fell below offering price on the first day of trading. The January 6, 2026 announcement of positive Phase 3 ONWARD results represented the company's most significant clinical milestone to date, triggering an approximately 82% stock price surge that day according to Pharmaphorum. However, the stock subsequently became volatile, declining approximately 18.51% on a separate trading day despite the positive clinical backdrop, as competitive pressure from J&J and Takeda's oral psoriasis programs led analysts to revise estimates. As of May 15, 2026, ALMS traded at $22.87 with a 52-week range of $2.76 to $30.60, reflecting the high binary risk and execution uncertainty typical of pre-commercial biotech companies approaching an NDA submission. Adverse milestones in the public record include the downsized IPO (planned at $274–315M, priced at a $250M total), the below-IPO first-day trading price, and the analyst price target cuts reflecting heightened competitive scrutiny. No regulatory enforcement actions, product recalls, or material litigation have been identified in available sources, though this absence should be treated as an open diligence item rather than a confirmed clean record, as pre-commercial biotechs can carry IP disputes, employment matters, or clinical adverse events not yet visible in the public record.[CO042, CO043, CO044, CO045]

1.6 Exhibits

2.1 Market Boundaries and Scope

Alumis's primary addressable market spans three autoimmune indications: moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). These indications share a common biology — dysregulated IL-23/IL-17 and Type I interferon signaling pathways — that TYK2 inhibition addresses mechanistically. The market boundary for this analysis is oral and injectable systemic therapies for moderate-to-severe disease; topical-only therapies and over-the-counter products are excluded. Biologics (anti-TNF, anti-IL-17, anti-IL-23) are included in the total indication TAM but not in the oral sub-market SAM that defines Alumis's primary competitive arena. The status-quo standard of care consists of: injectable biologics (AbbVie Skyrizi, Novartis Cosentyx, J&J Stelara, Amgen Enbrel/biosimilars) for patients with moderate-to-severe disease and prior systemic therapy failure; oral conventional DMARDs (methotrexate) and phosphodiesterase-4 inhibitors (Otezla/apremilast) for early systemic therapy; and, since September 2022, Sotyktu (deucravacitinib), the only approved oral TYK2 inhibitor pre-2026. A critical market shift occurred in March 2026 when J&J/Protagonist's ICOTYDE (oral IL-23 antagonist) received FDA approval, adding a new oral class that competes directly with TYK2 inhibitors for needle-averse patients seeking biologic-level efficacy. The oral immunology sub-market is accordingly no longer a single-product class as of Alumis's NDA submission cycle. Key inclusion/exclusion logic: SLE is included because Alumis has an active Phase 2b LUMUS program, but there is no approved TYK2 inhibitor for SLE as of May 2026. PsA is included because Sotyktu has European Commission approval for PsA and Alumis plans indication studies. The IBD (ulcerative colitis, Crohn's) adjacency is excluded from the primary TAM as Alumis has no active IBD program in its disclosed pipeline.

2.2 Market Sizing: TAM, SAM, and SOM

The combined global TAM across plaque psoriasis, PsA, and SLE exceeds USD 30 billion in 2026, computed by summing independently sized indication markets. Plaque psoriasis estimates range from USD 12.5–13.7 billion (conservative, narrowly scoped) to USD 23.8 billion (broader scope including all biologics used in psoriasis), reflecting definitional inconsistencies across analyst reports rather than true market volatility. PsA is estimated at USD 13.97 billion in 2026 (Fortune Business Insights), growing at ~11% CAGR through 2034. SLE is estimated at USD 3.68–3.71 billion in 2026, growing at 7.5–11.2% CAGR through 2031–2035 depending on the source. These are all-therapy TAM figures including biologics. The serviceable addressable market (SAM) for oral systemic therapy narrows significantly. In PsA, the oral segment holds approximately 20–28% of market revenue, with biologics commanding ~51–52%; applying oral share to the $14B PsA TAM implies a ~$3–4B oral PsA SAM. In psoriasis, the oral segment is substantially smaller relative to the biologic-dominant revenue base. The biologic psoriasis market alone is projected at $16.2 billion in 2026 (Intel Market Research), implying oral therapies represent a minor fraction today but one growing at the fastest rate. Combining oral-accessible share across the three indications yields a rough SAM of $5–9B for oral systemic immunology. The serviceable obtainable market (SOM) for the oral TYK2 inhibitor class specifically is estimated at ~USD 615 million in 2026 (Research and Markets), concentrated almost entirely in Sotyktu, with a CAGR of ~9.6% through 2032. This class-level SOM will expand as additional TYK2 inhibitors receive approval. Alumis's first-year SOM following NDA approval (expected 2027–2028 given H2 2026 filing) is not supportable from public data; it would depend on formulary access, pricing relative to Sotyktu and zasocitinib, and PASI 90/100 differentiation claims in prescriber detailing.

2.3 Buyer and Segment Map

The oral immunology market for plaque psoriasis, PsA, and SLE involves distinct buyer, user, and payer roles. The prescribing physician — primarily a board-certified dermatologist for psoriasis, a rheumatologist for PsA and SLE — makes the formulary-within-indication prescribing decision, but is constrained by payer prior authorization criteria, step-therapy requirements, and formulary tier placement. Patients are end users who exercise meaningful choice between orals and injectables, with needle aversion and administration convenience being documented adoption drivers for oral agents. Commercial payers (UnitedHealth, Cigna, Aetna, BCBS plans) and PBMs (Express Scripts, CVS Caremark, OptumRx) control formulary positioning through exclusion lists and step-therapy protocols, typically requiring failure of conventional DMARDs and/or apremilast before authorizing branded TYK2 or biologic therapy. Government payers (Medicare Part D, Medicaid) follow similar utilization management patterns but at lower net pricing after mandatory rebates. The effective payer is therefore the PBM/insurer, not the patient, for commercially meaningful volume. Segment-level adoption varies by indication: psoriasis patients skew younger, are often employed, and have private insurance coverage — making formulary tier directly relevant. SLE disproportionately affects women of reproductive age and people of color, with a higher Medicaid representation, where drug access timelines and rebate economics differ from commercial. PsA patients are often managed across both dermatology and rheumatology, creating a dual-physician prescribing dynamic for any new oral agent. Collectively, the highest-value buyer segment for Alumis's near-term launch (assuming psoriasis NDA first) is: younger, commercially insured, needle-averse, moderate-to-severe plaque psoriasis patients inadequately controlled on apremilast, with a dermatologist willing to prescribe a branded oral ahead of biologic step-up.

2.4 Growth Drivers and Adoption Constraints

The principal growth driver for the oral TYK2 inhibitor class is the convergence of biologic-level efficacy with oral administration convenience. Historically, moderate-to-severe psoriasis patients faced a trade-off: oral apremilast offered convenience at ~30% PASI 75 efficacy, while injectable biologics achieved PASI 90 in 50–70% of patients. Second-generation TYK2 inhibitors — Sotyktu, envudeucitinib, zasocitinib — now deliver PASI 75 rates of 75–80% and PASI 90 rates of 55–68%, closing the efficacy gap that historically drove biologic adoption. This shift is a structural market driver, not cyclical. A second driver is TYK2's regulatory safety profile. Unlike JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry an FDA black-box warning for major adverse cardiovascular events, thrombosis, and malignancy, deucravacitinib and next-generation TYK2 inhibitors have not received this warning — though Sotyktu's label notes uncertainty about whether TYK2 inhibition might share JAK risks, which has dampened enthusiastic prescribing. The absence of a black-box warning is a commercial advantage that prescribers and payers can leverage for formulary positioning. Key adoption constraints include: (1) Competitive crowding — three oral TYK2 inhibitors (Sotyktu, zasocitinib, envudeucitinib) plus ICOTYDE (oral IL-23) will compete in plaque psoriasis from 2027, compressing pricing power and increasing rebate demands; (2) Limited long-term safety data — only three years of follow-up for Sotyktu LTE, insufficient for lifetime chronic disease treatment; (3) Payer step-therapy protocols requiring prior treatment failure with cheaper agents before TYK2 authorization; (4) Indication-specific regulatory risk — no TYK2 inhibitor is approved for SLE, and Alumis's SLE market opportunity depends entirely on the Q3 2026 LUMUS Phase 2b readout; (5) Biosimilar competition for established biologics diverting payer savings that might otherwise widen access for new oral agents. The market is growing but the commercial access environment for a third entrant is materially more difficult than it was for Sotyktu's 2022 launch.

2.5 Competitive Market Dynamics and Oral Immunology Landscape

The oral immunology market for psoriasis and related indications is undergoing its most disruptive period since biologic approval in the early 2000s. Five forces are converging: (1) second-generation TYK2 inhibitors (envudeucitinib, zasocitinib) achieving biologic-level PASI 90 rates in Phase 3; (2) the first oral IL-23 antagonist (ICOTYDE) receiving FDA approval in March 2026 with projected $5B+ peak sales; (3) established injectable biologics (Skyrizi, Cosentyx, Tremfya) generating multi-billion revenue bases with strong clinical differentiation; (4) growing biosimilar competition for older biologics (adalimumab, etanercept) lowering payer costs on established therapy; (5) TYK2's pipeline density — 142 active programs — creating a crowded competitive runway through 2030. For Alumis specifically, the most commercially relevant comparison is envudeucitinib vs Sotyktu vs zasocitinib, as these are the three oral TYK2 agents in or near the NDA stage. Sotyktu's FY2024 revenue of $246 million and GlobalData's $2.9B projection to 2029 set the upper bound for the class near term. Zasocitinib's near-simultaneous NDA filing and Takeda's $4B acquisition investment signal serious commercial intent. ICOTYDE's March 2026 approval introduces an oral IL-23 competitor with superior head-to-head data vs Sotyktu. Envudeucitinib's clinical differentiation rests on maximal 24-hour TYK2 inhibition (a company claim not yet independently validated) and strong PASI 90/100 data from 1,700+ patients. The competitive market analysis suggests Alumis will enter a four-drug oral competition for psoriasis by 2027-2028, requiring formulary positioning, pricing discipline, and clinical differentiation to capture meaningful share of the $615M and growing TYK2 sub-market.

3.1 Direct TYK2 Inhibitor Competitors

The TYK2 inhibitor class is Alumis's most immediate competitive arena, currently anchored by Bristol Myers Squibb's Sotyktu (deucravacitinib) and imminently contested by Takeda's zasocitinib. Sotyktu received FDA approval in September 2022 for moderate-to-severe plaque psoriasis as the first-in-class selective TYK2 inhibitor. Its allosteric mechanism—binding the JH2 pseudokinase regulatory domain rather than the ATP-binding site—confers selectivity over JAK1/2/3, distinguishing it from broader JAK inhibitors that carry a class boxed warning. Sotyktu posted global net sales of approximately $246 million in 2024, a 45% year-over-year increase. In March 2026, the FDA expanded Sotyktu's label to include active psoriatic arthritis based on data from the pivotal POETYK PsA-1 and PsA-2 Phase 3 trials, making it the first TYK2 inhibitor approved for PsA. BMS broadened patient access further by launching a direct-to-patient platform in January 2026 at $950 per 30-day supply—an 86% reduction from the prior US list price of approximately $6,828. Despite early commercial traction, analyst downgrades temper peak sales expectations: Leerink Partners lowered its 2030 Sotyktu sales estimate to $832 million versus BMS's own guidance of over $4 billion, citing payer access friction and pricing pressure from emerging competitors. Takeda's zasocitinib (TAK-279, formerly NDI-034858) was acquired from Nimbus Therapeutics in December 2022 for $4 billion in upfront consideration, one of the largest single-asset immunology acquisitions in industry history. In Phase 3 LATITUDE trials in moderate-to-severe plaque psoriasis, approximately 70% of patients achieved sPGA 0/1 at week 16, with PASI 90 exceeding 50%; more than 90% of responders maintained benefit through 60 weeks, demonstrating strong durability. Takeda targets an NDA submission to the FDA in fiscal year 2026. Zasocitinib is also in Phase 3 for psoriatic arthritis, with a long-term extension study (NCT07286058) estimated to complete in December 2029. The TYK2 class also carries notable competitive failures. Ventyx Biosciences' VTX958 failed its Phase 2 SLE trial in April 2023 and was discontinued—forewarning the class-level SLE challenge Alumis is attempting to overcome in its LUMUS Phase 2b trial. Priovant Therapeutics' brepocitinib (PF-06700841), a dual TYK2/JAK1 inhibitor through a Pfizer-Roivant joint venture, failed to meet primary endpoints in a Phase IIb topical psoriasis study in 2023 and has been deprioritized for psoriasis in favor of dermatomyositis, uveitis, and lichen planopilaris. Both failures reinforce allosteric TYK2 selectivity as the required mechanistic profile for competitive differentiation in psoriasis.[CP001, CP002, CP003, CP004, CP005, CP006]

3.2 Oral Systemic Alternatives: JAK Inhibitors, PDE4, and Oral IL-23

Beyond TYK2 inhibitors, Alumis competes against a broadening oral systemic landscape. The most significant competitive event of 2026 is the FDA approval in March 2026 of Johnson and Johnson's icotyde (icotrokinra, formerly JNJ-2113), the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. The pivotal ICONIC program enrolled over 2,500 patients and demonstrated superiority over deucravacitinib in a head-to-head Phase 3 comparison, with approximately 70% of patients achieving IGA 0/1 and 55% achieving PASI 90 at week 16. Analysts predict icotyde could become the preferred oral option for psoriasis over Sotyktu and Otezla, setting a new efficacy benchmark that ESK-001 must match or surpass to justify a third oral entrant. ESK-001's ONWARD Phase 3 met all primary and secondary endpoints including outperformance of apremilast at every PASI benchmark; ESK-001 achieved PASI 90 of approximately 65% and PASI 100 of over 40% at week 24. No head-to-head trial between ESK-001 and icotyde has been conducted, leaving relative oral positioning unresolved. JAK inhibitors form the largest adjacent oral immunology class. AbbVie's Rinvoq (upadacitinib) is approved for plaque psoriasis, psoriatic arthritis, atopic dermatitis, and multiple additional indications, posting approximately 32% year-over-year growth in prescription value as of Q1 2026. However, all pan-JAK agents—including Rinvoq, Xeljanz (tofacitinib), and Olumiant (baricitinib)—carry an FDA class boxed warning covering serious infections, malignancies, major adverse cardiovascular events, and thrombosis, a structural safety disadvantage relative to TYK2-selective and IL-23 targeted agents. Pfizer's Xeljanz has experienced prescription volume decline of approximately 21% in 2026 due to generic entry and safety-driven formulary restrictions. Amgen's Otezla (apremilast), the pioneering oral PDE4 inhibitor for psoriasis, maintains the largest installed oral base, with a global market projected at $2.14–2.8 billion in 2025. Analyst surveys indicate Otezla is not meaningfully losing share to Sotyktu; growth from the TYK2 class appears to come primarily from biologic-treated patients rather than Otezla switchers. ESK-001's ONWARD trials used apremilast as an active comparator arm, and envudeucitinib outperformed apremilast at all efficacy endpoints, establishing a designed step-up displacement argument that positions ESK-001 as the preferred oral upgrade over Otezla for inadequate responders.[CP012, CP013, CP014, CP015, CP016, CP017]

3.3 Biologic Incumbent Landscape

Injectable biologics remain the clinical gold standard for moderate-to-severe psoriasis and define the efficacy ceiling that oral agents must approach to shift treatment algorithms meaningfully. The global biologic medications for psoriasis market was valued at approximately $14.5 billion in 2025, projected at $16.2 billion in 2026 at roughly 7–9% annual growth. IL-17 and IL-23 inhibitors collectively generate over $30 billion per year across psoriasis and adjacent indications including PsA. AbbVie's Skyrizi (risankizumab, IL-23 inhibitor) and Novartis's Cosentyx (secukinumab, IL-17A inhibitor) lead the biologic psoriasis market by revenue and prescriber share in 2026. Skyrizi is the fastest-growing biologic in the segment by volume; Cosentyx retains the broadest global commercial footprint. Eli Lilly's Taltz (ixekizumab, IL-17A) holds strong North American share. UCB's Bimzelx (bimekizumab, dual IL-17A/F inhibitor) is a recent entrant gaining share rapidly through its differentiated dual-IL-17 blockade. Johnson and Johnson's Stelara (ustekinumab, IL-12/23) faces biosimilar competition following US patent expiry in 2023 but retains use in PsA. Skyrizi typically achieves 65–75% PASI 90 and over 50% PASI 100 in pivotal trials, the benchmark ESK-001 must approach to support a near-biologic efficacy narrative for needle-averse patients. The strategic relevance of biologics to Alumis is as the efficacy ceiling ESK-001 must approximate, not displace wholesale. TYK2 inhibitors achieve anti-inflammatory effect by blocking cytokine signaling through IL-23, IL-12, and type-I interferon pathways via allosteric inhibition of the TYK2 JH2 pseudokinase domain, providing IL-23/IL-17 pathway suppression through a single oral mechanism that approximates targeted biologic activity. JAK inhibitors achieve similar but less selective immunosuppression via ATP-competitive kinase inhibition. Status-quo therapy—topical corticosteroids, methotrexate, cyclosporine, and phototherapy—constitutes the first-line standard patients cycle through before reaching advanced systemics. Biologic injectable list prices of $40,000–$50,000 annually contrast sharply with oral TYK2 agent list prices of $6,000–$7,000 per month, providing cost and convenience rationales that support oral adoption among biologic-naive and needle-averse populations.[CP023, CP024, CP025, CP026, CP027, CP028]

3.4 Feature, Pricing, and Go-to-Market Comparison

ESK-001's differentiation from Sotyktu rests on its claim of maximal 24-hour TYK2 inhibition with high selectivity. Alumis argues this allosteric binding profile achieves more complete suppression of IL-23, IL-12, and type-I interferon cytokine signaling than the approved 6 mg once-daily Sotyktu dose. Phase 2 open-label extension data at 52 weeks showed sustained PASI 90 of 61.3% and PASI 100 of 38.8% with no new safety signals—a durability dataset supporting the NDA application. ESK-001 outperformed apremilast at all PASI endpoints in ONWARD, providing a formulaic step-up claim over Otezla for payer and prescriber negotiations. No three-way head-to-head trial between ESK-001, zasocitinib, and icotyde exists; cross-trial comparisons remain the only available basis for relative positioning, with important limitations due to differences in patient populations, timepoints, and trial designs. Pricing in the oral psoriasis class is shifting toward access-oriented models. Sotyktu's prior US list price of approximately $6,828 per 30-day supply has been supplemented by BMS's direct-to-patient program at $950 per month for cash-pay patients starting January 2026. Otezla lists at approximately $3,700 per 30-day supply. ESK-001 pricing has not been set; Alumis's NDA has not yet been filed. Launch pricing comparable to or above Sotyktu's historical list price should be expected, with heavy payer rebating and step-edit navigation as the primary access barriers until real-world data accumulate. Go-to-market capabilities differ substantially across competitors. Sotyktu benefits from three years of commercial real-world data and BMS's established dermatology field force. Zasocitinib will launch backed by Takeda's global immunology infrastructure built around its multi-billion-dollar Entyvio franchise. Icotyde benefits from J&J's fully built-out global dermatology and immunology commercial organization. ESK-001, as Alumis's first commercial product, requires substantial commercial build or a co-promotion partnership. Alumis completed its IPO on Nasdaq in June 2024 at $16 per share, raising approximately $250 million; shares traded in the $22–24 range in May 2026. Total capital raised stands at approximately $529 million across Series A ($70M), Series B ($200M), Series C ($259M), and the IPO, providing adequate runway to fund NDA preparation and launch readiness.[CP031, CP033, CP034, CP036, CP037]

3.5 Moat Analysis and Competitive Risk

Alumis's potential competitive moats rest on three reinforcing layers. First, ESK-001's molecular profile—maximal 24-hour TYK2 inhibition with demonstrated absence of new safety signals across Phase 2 and Phase 3 studies—positions it as a potential clinical step-up over Sotyktu, pending head-to-head validation. Second, pipeline breadth provides strategic optionality beyond psoriasis: Alumis's LUMUS Phase 2b trial in SLE completed enrollment with topline data expected Q3 2026, and A-005, a CNS-penetrant allosteric TYK2 inhibitor, has Phase 2 initiation in multiple sclerosis planned for 1H 2026. A-005 Phase 1 data presented at ACTRIMS Forum 2025 confirmed cerebrospinal fluid drug levels comparable to or exceeding plasma levels, validating the CNS penetrance hypothesis. Third, a public capital structure with approximately $529 million in total raised capital provides access to equity markets to fund commercial build or partnership without near-term dilutive pressure. Competitive risks are material and multi-dimensional. Icotyde's FDA approval in March 2026 with proven head-to-head superiority over Sotyktu narrows the oral residual market available to ESK-001 before its expected commercial entry around 2H 2027 post-NDA filing and standard 10-month review. Zasocitinib's Phase 3 PASI 90 data are directionally competitive with ESK-001's, making a two-TYK2-inhibitor oral market plausible where ESK-001 becomes a third entrant rather than the primary disruptor. Takeda's integrated immunology commercial infrastructure—built through the global Entyvio franchise—gives zasocitinib a significant launch execution advantage over a first-product commercial organization. BMS's $950/month direct-to-patient pricing precedent for Sotyktu compresses class-level gross margin expectations before ESK-001 reaches market. Additionally, VTX958's Phase 2 SLE failure in 2023 demonstrates that TYK2 inhibition does not automatically translate across autoimmune indications, creating pipeline risk for Alumis's LUMUS program—though LUMUS differs in design and patient selection from the failed Ventyx study. Switching costs in the psoriasis market are moderate: patients on effective therapy rarely switch without loss of response, and step-edit formulary requirements delay initial brand access by months post-approval. Distribution power resides with specialty PBMs—Express Scripts, CVS Caremark, OptumRx—and specialty pharmacies with which Alumis has no pre-existing contractual relationships. PBM contracting capability is a first-product execution risk specific to a company with no commercial history.[CP038, CP039, CP040, CP041, CP042, CP043]

3.6 Exhibits

4.1 Revenue model: pre-commercial with first licensing income from Kaken Japan deal

Alumis is a clinical-stage biopharmaceutical company with no commercial product on the market. As of May 2026, the company has never generated revenue from drug sales. For fiscal year 2025, total reported revenue was $24.05 million, consisting of $17.39 million in license revenue and $6.66 million in collaboration revenue—both sourced exclusively from the collaboration and licensing agreement signed with Kaken Pharmaceutical Co., Ltd. in March 2025. The Kaken deal grants Kaken the rights to develop, manufacture, and commercialize ESK-001 (envudeucitinib) as a dermatology therapy in Japan, in exchange for $40 million in upfront and near-term co-development payments across 2025–2026, potential milestone and field option payments of up to approximately $140 million, and tiered royalties ranging from low double-digits to approximately 20% of Japan net sales. The revenue recognition profile follows ASC 606: the $17.4 million license obligation was recognized upon the March 2025 transfer of the license to Kaken; the development services and manufacturing services obligations are being recognized over time using an input method as Alumis performs its services. As of December 31, 2025, $17.6 million in transaction price remained unsatisfied and deferred—$14.3 million related to development services expected to be recognized through 2028, and $3.3 million related to a material right option that will be recognized when the option is exercised or expires. Prior to the Kaken deal, Alumis generated zero revenue in 2024. Any future commercial revenue depends entirely on FDA approval of envudeucitinib (NDA submission planned 2H 2026), successful market launch in psoriasis, and clinical readout in SLE (Phase 2b LUMUS trial data anticipated Q3 2026). Revenue from a potential Japanese commercial launch by Kaken would generate royalties but is years away. The pricing model for a US commercial launch—if envudeucitinib is approved—has not been publicly disclosed by management. Industry benchmarks for oral TYK2 inhibitors suggest a likely annual treatment cost in the five-figure range (Bristol Myers Squibb's approved TYK2 inhibitor Sotyktu carries a US list price of approximately $65,000 per year). Alumis has not confirmed any pricing assumptions.[CI009, CI010, CI011, CI012, CI013, CI014]

4.2 Capital raise history: $816M+ raised in equity since IPO including January 2026 follow-on

Alumis has financed its operations entirely through equity capital—no debt, credit facility, or project-finance structure appears in the 2025 10-K or any public filing. The company went public on July 1, 2024 on Nasdaq (ticker: ALMS), selling 13.125 million shares at $16.00 per share. Net proceeds from the IPO were $193.3 million after $16.7 million in underwriting discounts and other offering costs. On July 17, 2024, a concurrent private placement sold 2.5 million shares at the same $16 price to AyurMaya Capital Management for gross and net proceeds of $40 million. Prior to the IPO, Alumis raised approximately $259 million in a Series C round that closed in early 2024, led by Foresite Capital with participation from Samsara BioCapital, venBio Partners, Lilly Asia Ventures, and Cormorant Asset Management, among others. The company was previously incubated by Foresite Labs, and Foresite Capital held approximately 33% of shares at the time of the IPO. In Q2 2025, Alumis completed an all-stock merger with ACELYRIN, Inc. (formerly Nasdaq: SLRN), in which Alumis stockholders received approximately 55% and ACELYRIN stockholders approximately 45% of the combined company. The combined entity retained the Alumis name and is led by the existing Alumis executive team. At December 31, 2024, Alumis held approximately $289 million and ACELYRIN held approximately $448 million in cash and marketable securities, giving a pro-forma combined cash position of approximately $737 million ahead of the merger close. On January 9, 2026, Alumis completed an upsized underwritten follow-on offering of 20,297,500 shares at $17.00 per share (including full exercise of the underwriters' overallotment option). Net proceeds were $324.4 million after underwriting discounts. Post-offering pro-forma liquidity stood at approximately $632.9 million, combining the $308.5 million cash and marketable securities at December 31, 2025 with the $324.4 million net proceeds. Morgan Stanley, Leerink Partners, and Cantor served as underwriting representatives. Robert W. Baird also participated as an underwriter.[CI001, CI002, CI003, CI004, CI005, CI006]

4.3 Operating expenses and cash burn: $369.5M cash used in operations in 2025

Alumis's operating cost structure is dominated by clinical R&D spending, consistent with a late-stage Phase 3 biopharma. For fiscal year 2025, research and development expenses were $386.0 million, up from $265.6 million in 2024—an increase of $120.4 million or approximately 45%. The primary drivers were accelerated contract research and clinical trial costs for the Phase 3 ONWARD program in plaque psoriasis, increased headcount in R&D teams, and $9.5 million in one-time merger-related expenses (severance and stock-based compensation) related to the ACELYRIN integration. The 2024 baseline also included a $23.0 million clinical milestone payment related to the prior acquisition of FronThera, which inflates the year-on-year comparison. General and administrative expenses were $91.9 million in 2025, up from $35.2 million in 2024—an increase of $56.7 million. The main driver was $30.2 million in transaction and severance costs from the ACELYRIN merger. Underlying G&A growth (excluding merger costs) was approximately $26.5 million, reflecting increased headcount and professional consulting services to support the newly combined organization. Together, R&D and G&A totaled $477.9 million for 2025. Cash used in operating activities was $369.5 million in 2025, compared to $255.1 million in 2024. The gap between the $369.5 million operating cash outflow and the $243.3 million net loss is explained primarily by the $187.9 million non-cash bargain purchase gain from the ACELYRIN merger, which reduced GAAP net loss but did not generate cash. Stock-based compensation expense of $43.5 million partially offsets the cash-to-GAAP gap. On a quarterly basis, Q3 2025 operating loss was $115.3 million (up 17% from $98.4 million in Q3 2024), driven by Phase 3 acceleration spending. The company has consistently guided that loss and spending rates will remain elevated through the NDA submission.[CI017, CI018, CI019, CI020, CI021, CI022]

4.4 Capital adequacy: $633M pro-forma liquidity funds operations into Q4 2027

As of December 31, 2025, Alumis held $308.5 million in cash, cash equivalents, and marketable securities ($89.7 million cash, $218.8 million in marketable securities). The January 2026 follow-on offering added $324.4 million in net proceeds, bringing pro-forma liquidity to approximately $632.9 million. Management stated in the March 2026 10-K that the combined cash position—existing year-end 2025 balance plus the January 2026 net offering proceeds—is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027. The company confirmed no debt, credit facility, or project-finance obligation in its 2025 filings. At a 2025 operating cash burn rate of $369.5 million per year (approximately $92 million per quarter), the $632.9 million pro-forma position represents approximately 20 months of runway from year-end 2025, consistent with management's Q4 2027 guidance. The near-term 2026 spending plan includes Phase 3 ONWARD long-term data collection, the NDA preparation and submission, and Phase 2b LUMUS SLE trial activities. If the NDA is accepted and approved on the standard 12-month FDA review clock, Alumis would be nearing or entering commercial-stage spending roughly as its current runway expires. Several factors could compress the runway. First, NDA preparation and pre-commercialization activities (commercial team build-out, manufacturing scale-up, payer contracting) would require incremental capital before any product revenue materializes. Second, if SLE Phase 2b data supports progression into Phase 3, additional large-scale trial costs would be triggered. Third, the company maintains an active Form S-3 shelf registration filed July 3, 2025 (expires July 2028), with at least one prior use via a 424B5 prospectus supplement dated January 8, 2026, indicating ongoing reliance on at-the-market and follow-on offering capacity to top up the balance sheet. Short interest in ALMS stood at approximately 14.96% of float as of May 2026, with 9.01 days to cover—an elevated but not extreme short position that reflects investor debate about the timeline to profitability.[CI001, CI006, CI007, CI008, CI020, CI025]

4.5 Financial verdict: capital position adequate for NDA but commercialization requires additional raises

The positive financial case rests on three anchors. First, the capital position is solid: $632.9 million in pro-forma liquidity as of the run date funds the company well past the NDA submission and potentially through initial FDA review. The January 2026 follow-on offering at $17 per share—above the $16 IPO price—was upsized and overallotment was fully exercised, indicating robust institutional demand. Second, the Phase 3 ONWARD data validate the primary asset: both trials met all primary and secondary endpoints, with approximately 65% of patients achieving PASI 90 and more than 40% achieving PASI 100 at Week 24—results management describes as best-in-class for oral plaque psoriasis. Third, the Kaken deal provides the first proof of third-party validation of ESK-001's commercial value and contributes a deferred revenue stream of $17.6 million through 2028, partially offsetting operating costs. The negative case centers on four structural risks. First, the $369.5 million 2025 operating cash burn implies that commercialization—including commercial team hiring, manufacturing scale-up, and market access spending—will require additional capital raises beyond current runway. HC Wainwright downgraded ALMS to Neutral with a $25 price target in May 2026, citing valuation concerns as the stock approached or exceeded what their model supports for a pre-commercial asset. Second, the net loss improvement from $294.2 million (2024) to $243.3 million (2025) is almost entirely the result of a one-time, non-cash $187.9 million bargain purchase gain from the ACELYRIN merger; underlying operating losses worsened as Phase 3 spending accelerated. Third, the 2025 accumulated deficit reached $901.9 million—approaching $1 billion—with no clear path to profitability before at least 2027 at the earliest. Fourth, SLE Phase 2b (LUMUS) data in Q3 2026 and NDA acceptance in late 2026 each represent binary events; a negative outcome in either would likely trigger significant stock decline and complicate future financing. The analyst consensus as of May 2026 is Moderate Buy with an average price target of $40.10 against a recent stock price of approximately $22.87—implying ~75% upside—but the range from $14 (low) to $55 (high) reflects the wide outcome distribution. High short interest (14.96% float) confirms that a meaningful share of professional investors hold a bearish view on the probability-adjusted risk-reward. Financial diligence at this stage requires management-supplied cost-per-patient data for Phase 3 trials, a commercialization capital plan, and a specific post-approval revenue model to underwrite a valuation.[CI021, CI022, CI023, CI024, CI025, CI028]

4.6 Exhibits

5.1 Therapeutic pipeline and product-line map

Alumis is organized around a TYK2 franchise: two clinical-stage allosteric inhibitors of the JH2 pseudokinase domain of TYK2, a precision data analytics platform that rationally guides their deployment, and preclinical programs identified through the same platform. The lead asset is envudeucitinib (formerly ESK-001), an oral, highly selective, non-covalent small-molecule allosteric TYK2 inhibitor dosed twice daily at 40 mg. It is in Phase 3 for moderate-to-severe plaque psoriasis (ONWARD program), Phase 2b for systemic lupus erythematosus (LUMUS), and being profiled for additional immune-mediated diseases including psoriatic arthritis and rheumatoid arthritis. A-005 is a second-generation CNS-penetrant allosteric TYK2 inhibitor designed to cross the blood-brain barrier at pharmacologically relevant concentrations; it completed Phase 1 and is advancing to Phase 2 in multiple sclerosis in 2026. Lonigutamab, a subcutaneously delivered anti-IGF-1R monoclonal antibody for thyroid eye disease acquired via the ACELYRIN merger, is under strategic review as of Q1 2026. Beyond TYK2, the precision analytics platform has identified IRF5 and additional undisclosed targets, with at least one internally-developed program expected to report Phase 1 data in H2 2026. Alumis retains global rights for all assets except envudeucitinib in Japan (Kaken Pharmaceutical holds exclusive Japan dermatology rights).[CE001, CE015, CE025, CE026, CE027]

5.2 Envudeucitinib: allosteric mechanism, selectivity, and Phase 3 ONWARD evidence

Envudeucitinib achieves TYK2 selectivity through an allosteric mechanism: it binds the JH2 pseudokinase regulatory domain — a site structurally distinct from the JH2 domains of JAK1, JAK2, and JAK3 — inducing a conformational change that locks the catalytic JH1 domain in an inactive state, blocking ATP binding and downstream STAT phosphorylation. This indirect inhibition preserves JAK1/2/3 signaling activity, eliminating the cytopenia, infection risk, and lipid dysregulation associated with first-generation, non-selective JAK inhibitors. The molecular structure incorporates a deuterated methyl triazole moiety to enhance CYP1A2 metabolic stability and reduce metabolite-driven off-target effects, plus a cyclopropyl carboxamide group hypothesized to reduce hERG-associated cardiac repolarization risk. At 40 mg BID, oral administration sustains maximal IC90 TYK2 inhibition across the full 24-hour dosing interval — a pharmacodynamic threshold that Phase 2 data established as necessary for robust skin clearance responses. Phase 3 ONWARD1 (NCT06586112) and ONWARD2 (NCT06588738) enrolled more than 1,700 adults with moderate-to-severe plaque psoriasis randomized 2:1:1 to envudeucitinib 40 mg BID, placebo, or apremilast as an active comparator. Both trials met all co-primary endpoints (PASI 75 and sPGA 0/1 at Week 16) and all secondary endpoints with high statistical significance. Across both trials, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at Week 16 (p<0.0001 vs placebo). At Week 24, PASI 90 rates of 68.0% (ONWARD1) and 62.1% (ONWARD2), and PASI 100 rates of 41.0% and 39.5%, were observed — results that rank at the upper range for oral therapies in this indication. Envudeucitinib was superior to apremilast on all PASI endpoints at Week 24 (p<0.0001 in each trial). Scalp psoriasis clearance (ss-PGA 0/1) was achieved by approximately 75% of patients by Week 24. Patient-reported itch improvement was observed as early as Week 2, and DLQI 0/1 was achieved by 50% of patients by Week 12. Most common treatment-emergent adverse events were headache, nasopharyngitis, upper respiratory tract infection, and acne; the majority mild to moderate with no new safety signals through Week 24. An NDA submission to the FDA is planned for Q4 2026. ONWARD3 (NCT06846541), the long-term extension, is ongoing.[CE002, CE003, CE004, CE005, CE006, CE007]

5.3 A-005 CNS program and precision medicine platform

A-005 extends the TYK2 franchise into the central nervous system. The compound is designed to cross the blood-brain barrier, targeting neuroinflammatory conditions where TYK2 has a genetic rationale — primarily multiple sclerosis, but also potentially Parkinson's disease and other neurodegenerative conditions. In a Phase 1 study of 135 healthy participants, A-005 demonstrated dose-proportional pharmacokinetics, prolonged CSF exposure with concentrations comparable to or exceeding free drug plasma concentrations, and maximal TYK2 inhibition evidenced by pSTAT level changes. ECTRIMS 2025 pharmacology data further confirmed the approximately 1:1 plasma-to-CSF free drug ratio exceeding the IC90 threshold from cell-based assays. No serious adverse events were reported. A Phase 2 trial in multiple sclerosis is anticipated to initiate in H1 2026. If A-005 succeeds in MS, it would be the first approved oral CNS-penetrant allosteric TYK2 inhibitor for neuroinflammation. Alumis's precision data analytics platform is the enabling infrastructure driving both asset discovery and clinical biomarker strategy. The platform integrates genomic, proteomic, and clinical data to identify disease drivers, patient subtypes, and predictive biomarkers. In psoriasis, the STRIDE Phase 2 biomarker analyses demonstrated that envudeucitinib normalizes key cytokines and proteins in lesional skin — including IL-23, IL-17F, IL-22, IL-23A, IL-36A, DEFB4A, KRT16, and S100A9 — to levels observed in nonlesional tissue. Dose-dependent blood SIGLEC1 suppression from Week 2 in STRIDE provided early pharmacodynamic confirmation of maximal TYK2 pathway engagement at 40 mg BID. These biomarker signatures inform dose selection and patient enrichment strategies for the SLE and CNS programs. Alumis was incubated by Foresite Labs (Foresite Capital affiliate), which continues to provide genetic target exploration services under an agreement through December 2026. TYK2 genomic analyses by Alumis identify contributions to approximately 20 immune-mediated conditions, providing the rational basis for the multi-indication franchise strategy.[CE012, CE013, CE014, CE015, CE016, CE017]

5.4 Manufacturing, supply chain, and commercial partnerships

Alumis has no internal manufacturing capabilities. All clinical supply production is outsourced to third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) under agreements typical of late-stage clinical-stage biotechs. The identities of primary CMO partners for envudeucitinib drug substance and drug product are not publicly disclosed in SEC filings as of Q1 2026, representing a material supply chain diligence gap. A commercial-scale manufacturing readiness plan has not been described publicly, though the 10-Q identifies procurement of commercial manufacturing capacity as a planned step. The ACELYRIN merger added a prepaid credit voucher for clinical manufacturing valued at approximately $11.4M at closing, applicable to lonigutamab clinical supply from a former ACELYRIN CMO. The Kaken Pharmaceutical (Japan) collaboration, signed March 2025, grants Kaken an exclusive license to develop, manufacture, and commercialize envudeucitinib in Japan for dermatology indications. Alumis received a $20M upfront payment and is entitled to milestone and royalty payments; Kaken also reimburses $20M in global development costs through end of 2026. Kaken retains options to expand the license to rheumatology and gastroenterology. Alumis retains global rights for all other geographies and all indications including SLE and CNS programs. As of March 31, 2026, Alumis held $569.5M in cash and marketable securities, which management believes is sufficient for at least 12 months of operations from the May 2026 10-Q issuance date, covering the NDA submission and LUMUS topline readout milestones.[CE023, CE024, CE027, CE035]

5.5 Regulatory compliance, quality controls, and development roadmap

All Alumis clinical programs are conducted under U.S. FDA IND applications, with all trials registered on ClinicalTrials.gov per Good Clinical Practice requirements. The Phase 3 ONWARD program carries NCT numbers NCT06586112, NCT06588738 (ONWARD1, ONWARD2), and NCT06846541 (ONWARD3). The LUMUS Phase 2b SLE trial is registered as NCT05966480. Manufacturing partners are expected to operate under GMP for clinical supply, with commercial-scale GMP compliance required for NDA submission. GLP preclinical studies underpin all IND-enabling toxicology packages, and IRB oversight is in place at all investigational sites. The competitive regulatory context presents a calibrated risk. The FDA has issued a class-wide black-box warning for JAK inhibitors covering infection, malignancy, major adverse cardiovascular events, and thrombosis — driven by data from higher-affinity JAK1/2/3 inhibitors. Alumis argues that the allosteric, TYK2-selective mechanism of envudeucitinib is exempt from these JAK class concerns, given its preservation of JAK1/2/3 activity. Deucravacitinib (Sotyktu), which shares this allosteric JH2 mechanism and was FDA-approved in 2022, received its label without a black-box warning, establishing regulatory precedent. The envudeucitinib NDA will face review of the full safety database from ONWARD1/2 plus ONWARD3 long-term extension data; any new signal in the extension trial or the SLE cohort could influence label scope. Alumis's IP portfolio for envudeucitinib and A-005 is referenced but not enumerated in public filings — the breadth and expiry horizon of composition-of-matter and method-of-use patents remain a diligence gap.[CE010, CE028, CE029, CE030, CE033]

5.6 Exhibits

6.1 Patient Population Segmentation

Alumis operates as a pre-commercial clinical-stage company; no revenue-generating customers exist as of May 2026. The customer framework is therefore forward-looking, segmented across three principal axes: patients, prescribers, and payers. The primary patient segment is US adults with moderate-to-severe plaque psoriasis. The National Psoriasis Foundation reports 7.5 million US adults have psoriasis as of March 2026, with approximately 1.9 million (roughly 1 in 4) meeting the moderate-to-severe threshold that justifies systemic therapy -- the direct addressable universe for envudeucitinib. Plaque psoriasis constitutes 80-90% of all psoriasis presentations and is the sole Phase 3 indication pursued. Two expansion segments are in clinical development. Psoriatic arthritis affects approximately 912,000 US adults per NHANES 2017-2020 (ACR 2024), and Sotyktu received FDA approval for PsA in March 2026, validating TYK2 inhibition in joint disease. Systemic lupus erythematosus affects approximately 204,000 US adults per CDC estimates; Alumis's Phase 2b LUMUS trial has topline data expected Q3 2026. Prescriber customers are US dermatologists (~12,000-13,000 practicing) and rheumatologists (~6,500-7,000). Payer customers -- commercial health plans and PBMs -- represent the third axis; UHC and Cigna already impose step-therapy prior authorisation for Sotyktu, establishing the formulary precedent envudeucitinib will face. The global psoriasis drugs market was $20.05 billion in 2025, growing to an estimated $32.94 billion by 2031 at 8.63% CAGR; oral small molecules (including TYK2 inhibitors) are the fastest-growing segment at nearly 15% CAGR. [CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Prescribers, Payers, and Access Architecture

Despite envudeucitinib's strong clinical profile, the prescriber and payer access landscape presents material adoption headwinds, as illustrated by Sotyktu's commercial trajectory. On the prescriber side, a December 2025 Recon Strategy analysis of Deutsche Bank survey data found that 50% of US dermatologists ranked Sotyktu seventh or eighth among systemic therapies on efficacy, and 65% ranked it in the bottom two on pricing and access. This prescriber tepidity reflects both clinical conservatism -- high-efficacy biologics (IL-17 and IL-23 agents with monthly or quarterly dosing) remain preferred -- and formulary friction that limits patient access. BMS acknowledged the access problem explicitly when it launched a DTC campaign in September 2025 at more than 80% below list price ($6,678/30-day WAC). On the payer side, UnitedHealthcare's prior authorisation policy (current 2026) requires documented topical corticosteroid failure plus a 3-month methotrexate trial or prior failure of an FDA-approved systemic targeted agent, with prescribing dermatologist attestation and a 12-month authorisation. Cigna's March 2026 policy revision similarly requires topical and conventional systemic failure before coverage. These two payers collectively cover more than 55 million commercial lives, making step-therapy compliance a de facto prerequisite for any TYK2 inhibitor to achieve meaningful script volume. For envudeucitinib, this means the practical first-access addressable universe is the subset of moderate-to-severe psoriasis patients who have already failed topicals, methotrexate, and biologics -- a narrower and more medically complex cohort than the full 1.9 million. [CU019, CU020, CU021, CU022, CU023]

6.3 Trial Evidence and Named Stakeholder Proof

The most concrete customer evidence available pre-launch derives from the ONWARD Phase 3 programme -- 1,700+ patients randomised across 156 global investigator sites in ONWARD1 (NCT06586112) and ONWARD2 (NCT06588738), with enrollment completed May 2025 and topline data presented at AAD 2026 on March 28. Efficacy results were exceptional for an oral agent. At week 16, approximately 74% of envudeucitinib patients achieved PASI 75 and 59.5% reached sPGA 0/1, meeting both co-primary endpoints with statistical significance (p<0.001) in both trials. By week 24, approximately 65% achieved PASI 90 and approximately 40% achieved PASI 100 -- efficacy rankings that rival or exceed several marketed biologics in indirect comparisons. Envudeucitinib outperformed apremilast on all PASI endpoints at week 24, delivering a key secondary win that supports formulary differentiation. Itch relief (patient- reported NRS score) was detectable by week 2, providing rapid patient- perceived benefit that supports adherence and word-of-mouth demand. The safety profile through week 24 was consistent with prior Phase 2 data; adverse events were mostly mild-to-moderate (nasopharyngitis, headache, acne, upper respiratory infections) with no new safety signals. Dr. Andrew Blauvelt, MD, MBA (Blauvelt Consulting) -- a well-published TYK2 expert and former Oregon Medical Research Center faculty -- served as a principal ONWARD investigator and presented results at AAD 2026. The National Psoriasis Foundation highlighted envudeucitinib as an oral breakthrough candidate in its AAD 2026 coverage, lending patient- advocacy credibility that complements the clinical evidence. [CU008, CU009, CU010, CU011, CU012, CU013]

6.4 Sotyktu Adoption Trajectory as Commercial Comparator

Sotyktu (deucravacitinib, BMS) is the only approved TYK2 inhibitor and serves as the most instructive commercial comparator for envudeucitinib's expected launch curve. Sotyktu was approved in September 2022. Global net sales were approximately $246 million in 2024 and grew ~19% to $291 million in 2025 -- directionally positive but well below the blockbuster trajectory originally forecast. GlobalData's peak sales projection of $2.9 billion by 2029 implies roughly tenfold growth from 2025, requiring sustained double-digit annual growth for four consecutive years. The Recon Strategy adverse analysis identifies the core headwinds: dermatologist perception of Sotyktu's efficacy as insufficient to displace high-efficacy biologics, combined with access friction that depresses net patient volume even when prescriptions are written. The comparison to subcutaneous IL-17 and IL-23 agents (PASI 90 rates of 70-80%; PASI 100 of 40-55%) remains unfavourable for TYK2 in prescriber- guided treatment initiation, though oral convenience is a patient preference differentiator. For Alumis, the lesson is that efficacy data alone is insufficient -- payer contracting, prescriber education, and formulary positioning must accompany launch to avoid Sotyktu-like adoption inertia. Envudeucitinib's PASI 100 rates (~40%) and the apremilast superiority claim could support a differentiated formulary message, but head-to-head data versus Sotyktu do not exist. [CU017, CU018, CU019, CU020, CU038]

6.5 Expansion Pathways and Concentration Risk

As of May 2026, Alumis has a single asset in a single approved indication (NDA planned H2 2026), representing acute concentration risk on both the commercial and scientific dimensions. The most near-term customer expansion pathway is psoriatic arthritis. With Sotyktu receiving FDA PsA approval in March 2026, the regulatory precedent for TYK2 inhibition in joint disease is established. However, Alumis has not yet disclosed a pivotal PsA trial design, making this segment speculative beyond Phase 2 data. The NHANES-derived PsA prevalence of ~912,000 US adults represents a meaningful patient segment, but the commercial window depends on Phase 3 data not yet available. The SLE expansion (LUMUS Phase 2b, topline Q3 2026) is more imminent but earlier in development. A positive LUMUS readout would unlock an incremental patient segment of ~204,000 US adults; a negative result would eliminate SLE as a near-term customer opportunity. Competitive concentration risk derives from the TYK2 and oral immunology pipeline. PatSnap data identifies multiple late-stage TYK2 programmes (Takeda, Boehringer Ingelheim, Sun Pharma) alongside next- generation IL-17/IL-23 biologics. BID dosing for envudeucitinib is a patient convenience disadvantage versus QD alternatives; Alumis is developing a QD modified-release formulation, but this is not yet in pivotal trials. Alumis has not disclosed a specialty pharmacy partner, hub services contract, or patient support programme as of May 2026, leaving the commercial infrastructure pathway unverified. [CU028, CU029, CU031, CU032, CU033, CU034]

7.1 Regulatory and Legal Risk

Alumis's primary regulatory risk is the FDA NDA review for envudeucitinib in plaque psoriasis, planned for submission in H2 2026. Although ONWARD1 and ONWARD2 met all primary and secondary endpoints with high statistical significance—74% PASI 75 and 59% sPGA 0/1 at Week 16, deepening to approximately 65% PASI 90 and over 40% PASI 100 by Week 24—NDA approval is not guaranteed. The FDA may issue a complete response letter (CRL) citing Chemistry, Manufacturing and Controls (CMC) deficiencies at CDMOs, request additional safety data from the ONWARD3 long-term extension, or require a Risk Evaluation and Mitigation Strategy (REMS) that constrains commercial uptake. The standard NDA review cycle is 10 months from filing; a Priority Review would compress this to 6 months. Alumis's 10-K explicitly acknowledges that regulatory authorities may disagree with study design, interpretation of data, or impose additional requirements even after reviewing clinical trial design. The TYK2-class labeling question is partially resolved. Deucravacitinib (Sotyktu), the only approved TYK2 inhibitor, does not carry the JAK inhibitor boxed warning for major adverse cardiovascular events, cancer, thrombosis, and death that was mandated for tofacitinib, baricitinib, upadacitinib, and ruxolitinib. However, Sotyktu's label does include prominent warnings on infections, tuberculosis, malignancy, and hypersensitivity, and explicitly states that it is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition. For envu, this creates residual labeling uncertainty—the FDA may apply similar precautionary language that could affect prescriber adoption, particularly in cardiovascular-risk patient populations. Legal risk is elevated by two active matters. The ACELYRIN securities class action, filed on behalf of IPO investors alleging materially false and misleading statements about izokibep, was inherited through the May 21, 2025 ACELYRIN Merger. Defendants filed a motion to dismiss the second amended complaint on February 19, 2026; the litigation remains active. A separate lawsuit by Climb Bio against Alumis and ACELYRIN disputes a milestone payment obligation on the budoprutug asset. Neither matter has been resolved, and Alumis's Q1 2026 earnings commentary flagged this litigation as a source of management distraction and potential financial liability. IP risk is moderate: Alumis holds patents on envu's chemistry and process, and BMS Sotyktu's core compound patents expire November 7, 2033, meaning no authorized generic competition for the TYK2 class before that date in the U.S.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Clinical and Operational Risk

Single-asset concentration is the defining operational risk at Alumis. Envudeucitinib represents the entirety of the near-term commercial pathway; all clinical, regulatory, and commercial execution depends on this single molecule. The company discontinued its Phase 2a envu trial in non-infectious uveitis in June 2024 when efficacy results did not meet its clinical threshold, demonstrating that TYK2 inhibition does not generalize to every indication. The SLE Phase 2b LUMUS trial—a 48-week study with topline data expected in Q3 2026—is the next high-stakes binary readout. Enrollment in LUMUS has been challenging because patients must have active disease at screening; the 10-K explicitly flags that longer clinical trials have heightened participant withdrawal risk. Manufacturing relies entirely on third-party CDMOs and contract manufacturers. Alumis has no manufacturing facilities, and API for envu is sourced principally from manufacturers in India and Taiwan. The company acknowledges in its 10-K that it does not yet have long-term supply arrangements in place and is still implementing a redundant supply chain for envu API, drug product, and critical raw materials. During this implementation period, a single-source API disruption—whether from geopolitical tensions, an FDA warning letter to a CDMO, a quality event, or force majeure—could halt clinical supply or delay NDA CMC documentation. Industry data from 2025-2026 shows FDA enforcement actions against contract manufacturers increased approximately 50% in 2025, and over 40% of pharma companies reported supply chain disruptions due to geopolitical tensions. Long-term safety is an ongoing concern. Alumis's 10-K notes that as more patients are exposed to envu over longer periods in ONWARD3, additional SAEs and AEs will accumulate. Certain conditions are more frequent in psoriasis patients—obesity, cardiovascular disease, psoriatic arthritis, depression—creating confounding factors for attributability. Deucravacitinib's label, which serves as a regulatory precedent, includes warnings for rhabdomyolysis, a rare but severe adverse event that could surface in long-term extension data. The theoretical oncogenicity risk from prolonged immune modulation is monitored but unquantified at current trial durations.[CR010, CR011, CR012, CR013, CR014, CR015]

7.3 Competitive and Technology Risk

The TYK2 inhibitor competitive landscape has intensified materially in 2026. Takeda's zasocitinib (acquired from Nimbus Therapeutics for $4 billion in 2022) delivered Phase 3 LATITUDE data at the 2026 American Academy of Dermatology meeting showing PASI 90 rates of 61.3% and 51.9% in two trials at Week 16, with PASI 100 of 33.4% and 25.2%. Takeda plans to file for U.S. approval in its fiscal year 2026 and forecasts peak revenue of $3–6 billion. The critical dosing differentiation is that zasocitinib is once-daily, while envudeucitinib is twice-daily—a potentially material adherence disadvantage in a primary care and dermatology setting where JAK and TYK2 inhibitors compete on convenience. Takeda's president of R&D publicly identified dosing as an area of "considerable differentiation" over Alumis. BMS Sotyktu (deucravacitinib), the first-mover, achieved PASI 90 rates of only 32–42% in Phase 3 and is being outcompeted on efficacy by both zasocitinib and envu; however, BMS received FDA approval for Sotyktu in psoriatic arthritis in March 2026, expanding its commercial moat while Alumis has no approved product. J&J and Protagonist's Icotyde (injectable IL-23 receptor antagonist) received FDA approval based on PASI 90 rates up to 55% at Week 16, adding a high-efficacy injectable competitor at the time envu enters the market. The Ventyx Biosciences VTX958 program provides a cautionary read-across. VTX958 is an allosteric TYK2 inhibitor that failed its primary symptomatic endpoint in both a Phase 2 psoriasis trial (insufficient efficacy vs. the competitive bar, November 2023) and a Phase 2 Crohn's disease trial (missed CDAI primary endpoint despite dose-dependent endoscopic improvement). Ventyx discontinued internal development of VTX958. While envudeucitinib is mechanistically distinct (it achieves maximal TYK2 inhibition blocking both IL-23/IL-17 and Type I interferon), the VTX958 failures demonstrate that allosteric TYK2 inhibitors as a class do not guarantee efficacy in every immune indication. The SLE indication, in particular, shows mixed evidence across the class. If LUMUS fails, the read-across to other immune indications would be questioned. Chinese pharmaceutical companies are also filing TYK2 patents at accelerating rates, representing a longer-term competitive and IP pressure vector internationally, particularly in Asia-Pacific markets where the global TYK2 opportunity extends.[CR017, CR018, CR019, CR020, CR021, CR022]

7.4 Partner and Dependency Risk

Alumis's revenue is entirely derived from a single collaboration agreement with Kaken Pharmaceutical, the company's sole commercial partner. While this relationship validates envu's commercial potential in Japan, it creates extreme revenue concentration risk: any dispute, termination, or renegotiation of the Kaken collaboration eliminates 100% of Alumis's current revenue. The terms and milestone schedule of the Kaken agreement are not fully public, creating information asymmetry for investors. Manufacturing dependency on CDMOs is a structural risk for clinical supply, NDA CMC filing, and eventual commercial launch. Alumis has no in-house manufacturing and operates on purchase-order basis without long-term supply arrangements currently in place. The principal API suppliers are located in India and Taiwan, both geographies subject to geopolitical volatility, FDA inspection activity, and supply chain disruptions. The 2025–2026 pharma industry backdrop shows FDA enforcement actions increasing 50% against CMOs and 40%+ of companies experiencing supply disruptions from geopolitical tensions. A GMP failure at a CDMO—particularly during the pre-NDA commercial launch readiness phase—could delay the regulatory filing or approval, compressing the commercial window. CRO dependency for ONWARD3 long-term extension and the LUMUS SLE trial creates execution risk that Alumis acknowledges in its 10-K: the company relies on CROs and clinical sites for proper and timely conduct, and has limited influence over their performance. Protocol deviations at trial sites, slow enrollment in LUMUS, and data integrity issues could affect the quality of regulatory submissions. The $300M ATM offering agreement with Cantor Fitzgerald provides financial flexibility, but capital-markets access depends on Alumis's stock price and market conditions at time of use— a binary NDA outcome could impair access to ATM capital precisely when it is most needed.[CR024, CR025, CR026, CR027]

7.5 Financial Risk

Alumis is a clinical-stage company with no commercial revenue from products, an accumulated deficit of $901.9 million as of December 31, 2025, and net losses of $243.3 million in FY2025 and $294.2 million in FY2024. The quarterly operating cash burn was $87 million in Q1 2026, consistent with late-stage clinical development costs. Management's stated belief that current cash—$570 million as of March 31, 2026, following a $324 million public offering in January 2026—funds operations for at least 12 months from March 2026 means that additional financing will likely be required before or shortly after the H2 2026 NDA filing. If the NDA is filed on schedule and approved within the standard 10-month review cycle, commercialization expenses will dramatically increase the burn rate precisely when the company needs to raise capital or negotiate a commercial partnership. Dilution risk is material and ongoing. The March 2026 $300 million ATM agreement with Cantor Fitzgerald supplements equity raises but at-the-market sales create continuous share dilution. Each successive capital raise—including the $324M offering in January 2026—dilutes early investors. Alumis also holds $51 million in acquired in-process R&D intangible assets tied to the lonigutamab program; following the decision to explore strategic alternatives for lonigutamab, a non-cash impairment charge is possible. Revenue concentration in Kaken Pharmaceutical means that any collaboration dispute would immediately eliminate all revenue while the company continues burning cash at $87M per quarter. The binary nature of the NDA outcome creates a financial cliff. A CRL from the FDA would trigger a significant decline in market capitalization, potentially impairing the ability to raise equity at reasonable terms and threatening the commercialization plan. Unlike commercial-stage biotechs, Alumis has no cash-generating products to buffer a setback. The IPO in June 2024 raised approximately $250 million; subsequent equity issuances have extended runway, but the company remains structurally dependent on favorable capital market conditions and a successful NDA outcome.[CR028, CR029, CR030, CR031, CR032]

7.6 People and Execution Risk

CEO Martin Babler, appointed in September 2021 and serving as President, CEO, and Chairman of the Board, is the central architect of Alumis's late-stage development and IPO strategy. His prior experience leading Principia Biopharma through its $3.7 billion acquisition by Sanofi, combined with a background at Genentech and Eli Lilly, makes him a credible leader in the TYK2 and immuno- oncology investor community. His departure or incapacitation would disrupt investor confidence, disrupt the NDA process narrative, and risk key institutional relationships. Alumis's 10-K explicitly identifies dependence on its management team and key scientific personnel as a material risk, and the company has not publicly disclosed a formal succession plan. The depth of the clinical leadership team under CMO Dr. Jörn Drappa is critical to executing the NDA submission—a process that requires coordinated CMC, clinical, regulatory, and biostatistics expertise. The 10-K highlights the challenge of attracting and retaining qualified clinical, scientific, and operations personnel; in a competitive Bay Area biotech environment with multiple well-capitalized peers, turnover in the NDA team at a critical juncture (H2 2026 submission) would be highly disruptive. The merger integration of ACELYRIN adds organizational complexity, given that ACELYRIN's discontinued lead program (izokibep) may have created morale and retention issues within the combined workforce. Governance risk arose during the ACELYRIN merger process: Trium Capital, an ACELYRIN investor, publicly pressured ACELYRIN's board to reject the Alumis merger and instead pursue liquidation, arguing liquidation would yield higher returns to shareholders. While the boards of both companies recommended the merger—approved by shareholders on May 13, 2025—this episode reflects investor skepticism about the terms of the transaction and management allocation of capital. The governance concern is now embedded in Alumis's shareholder base post-merger and could surface in future proxy contests if execution falters.[CR033, CR034, CR035]

7.7 Mitigations, Monitoring, and Kill Criteria

Alumis's primary risk mitigations include the positive ONWARD Phase 3 results providing strong NDA support, a $570M cash position providing multi-year runway, and the TYK2 class's established regulatory precedent via Sotyktu avoiding the JAK boxed warning. The company is implementing redundant supply chain for API, drug product, and critical raw materials prior to NDA submission, which is best practice for NDA CMC filing. The ongoing ONWARD3 long-term extension provides additional safety data for the regulatory package. The precision data analytics platform and GWAS-driven target selection provide scientific rationale for the SLE and pipeline-in-a-pill strategy beyond psoriasis. Three thesis-break triggers require immediate investment re-evaluation: (1) An FDA complete response letter (CRL) on the envu NDA in plaque psoriasis—whether citing efficacy, safety, CMC, or other deficiencies—would collapse the near-term commercial narrative and impair capital-raising ability at precisely the worst moment; (2) A material serious adverse event signal in ONWARD3 long-term extension not present in ONWARD1/2—particularly a signal consistent with JAK-class adverse events (cardiovascular, malignancy, thrombosis)—would trigger a clinical hold, label restriction, or program reconsideration; (3) LUMUS Phase 2b failure in SLE would eliminate the pipeline-in-a-pill narrative, reducing the commercial addressable market to psoriasis only and making the competitive fight against zasocitinib's once-daily dosing advantage more acute. Key monitoring indicators: FDA pre-NDA meeting outcome and CMC feedback from Q2–Q3 2026; LUMUS topline Q3 2026; ONWARD3 long-term extension safety updates at medical meetings; Takeda zasocitinib NDA filing and FDA review timeline; quarterly cash burn versus treasury balance; ACELYRIN class action MTD ruling; Kaken collaboration milestone payment schedule. Annual diligence asks: audited financial statements, supply chain redundancy confirmation, CDMO audit status, NDA acceptance/ refusal to file letter, and clinical team retention data.[CR036, CR037, CR038, CR039, CR040]

7.8 Exhibits

8.1 Investment Thesis and Anti-Thesis

Alumis presents a compelling buy thesis anchored in three pillars: class-leading clinical efficacy, a large underpenetrated addressable market, and a well-capitalized pre-approval balance sheet. Phase 3 ONWARD1 and ONWARD2 data confirm that envudeucitinib achieves PASI 90 rates of approximately 65% and PASI 100 rates of approximately 40% at Week 24, materially exceeding deucravacitinib (Sotyktu) benchmarks of roughly 40% PASI 90. The psoriasis drugs market was estimated at $21.78 billion in 2026 and is growing at approximately 8.6% annually through 2031, while the more specific TYK2 inhibitor segment is expanding at 15% CAGR toward $7.4 billion by 2033. Alumis's NDA filing in H2 2026 could unlock commercial launch in 2027, with a peak sales potential in psoriasis alone estimated at $2–4 billion globally. The anti-thesis centers on binary regulatory and commercial execution risk: the entire investment thesis depends on a single drug receiving FDA approval, launching successfully in a competitive market already occupied by deucravacitinib and the newly approved oral IL-23 inhibitor icotrokinra. Elevated short interest (~15.5% of float) signals significant institutional bearishness, and any NDA delay or additional FDA data requests could reprice the stock sharply downward. The company generated only $1.74M in Q1 2026 revenue, relies on a single licensing partner (Kaken Pharmaceutical), and must commercialize into a market where large biologics incumbents control formulary access. [CV001, CV002, CV003, CV013, CV014, CV015]

8.2 Valuation Context and Comparable Analysis

At $24.86 per share and approximately $3.16 billion market cap as of May 18, 2026, ALMS trades at a steep premium to tangible assets but a meaningful discount to analyst consensus targets. Wall Street carries a strong buy consensus across 10–13 analysts, with average price targets of approximately $40 per share (range $25–$55) implying roughly 60% upside. Leading targets include Oppenheimer at $55, Wells Fargo at $51, and Morgan Stanley at $38. This valuation is broadly consistent with precedent for late-stage pre-commercial biotechs with class-leading Phase 3 data: the psoriasis and autoimmune space has seen acquisitions commanding 50–100%+ premiums. The January 2026 upsized public offering raised $345.1 million at $17 per share; the stock has since appreciated ~46%, reflecting strong demand for the Phase 3 efficacy story. Comparable analysis anchors to similarly positioned pre-NDA biotechs and recently transacted dermatology and immunology assets. Takeda's zasocitinib is the closest competitive complication, also planning a 2026 FDA filing with PASI 90 >50%. BMS Sotyktu, the only approved oral TYK2 inhibitor, generated approximately $190M in 2024 revenue, well below peak forecasts, revealing the challenge of formulary access and biologic incumbent entrenched positioning. An EV/peak-sales multiple of 1.0–1.5x applied to an envudeucitinib psoriasis peak sales estimate of $2.5B yields a fair-value range of approximately $3.2–$4.2B, suggesting the current market cap is fair to modestly undervalued assuming successful launch. [CV004, CV005, CV006, CV007, CV008, CV009]

8.3 Scenarios, Risks, and Thesis-Break Triggers

The bull case envisions FDA approval of envudeucitinib for psoriasis in mid-2027 followed by strong commercial launch, Phase 2b SLE data supporting a second NDA in 2028, and potential partnership or acquisition by a large pharma at a significant premium. Under this scenario, valuation could reach $6–8B within 18–24 months of approval as commercial ramp begins and the multi-indication pipeline gains credibility. The base case assumes on-time NDA filing and approval, a moderate commercial launch aided by superiority data versus Sotyktu, and partial SLE proof of concept, supporting a valuation of $4–5B. The bear case—NDA rejection, FDA request for additional studies, or unexpected safety signal—could reset the stock toward $0.9–$1.5B, representing a 50–70% decline from current levels. Key thesis-break triggers include: any FDA complete response letter citing safety or efficacy deficiencies; SLE Phase 2b LUMUS data missing on its primary BICLA endpoint in Q3 2026; loss of key management including CEO Martin Babler; and the securities class action lawsuit from the Acelyrin acquisition period escalating materially. Short interest at approximately 15.5% with 13.5 days to cover reflects institutional conviction in the bear case. The Q3 2026 SLE readout and H2 2026 NDA filing are the two binary events that will most likely either validate or rupture the current valuation. [CV030, CV031, CV032, CV033, CV034, CV035]

8.4 Exit Readiness and Final Diligence Asks

Alumis is already publicly traded (NASDAQ: ALMS), completing the IPO exit path for early investors in June 2024. The remaining exit mechanisms for investors are: stock appreciation through FDA approval and commercial launch, targeted at analyst consensus of $40 per share; M&A by a large pharmaceutical company seeking oral immunology capabilities, with Alumis an attractive target for AbbVie, Pfizer, or Sanofi given its class-leading TYK2 data; and partnership or licensing deals for ex-US rights or the SLE indication that could validate the pipeline while providing non-dilutive capital. Immediate diligence asks focus on the NDA package readiness covering manufacturing CMC, clinical module completeness, and pediatric study waivers; SLE LUMUS primary endpoint details; competitive positioning against Takeda zasocitinib in timing and label; and payer strategy for formulary positioning at launch. The company's cash runway of approximately $569.5M should fund operations through late 2027, providing coverage through an expected FDA review period of 12 months post-filing. The Kaken Pharmaceutical partnership revenue concentration remains a vulnerability if that agreement is renegotiated. [CV039, CV040, CV041, CV042]

8.5 Exhibits